

Ladan Zand

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/389052/publications.pdf>

Version: 2024-02-01

40
papers

1,183
citations

394421

19
h-index

395702

33
g-index

40
all docs

40
docs citations

40
times ranked

1512
citing authors

#	ARTICLE	IF	CITATIONS
1	C3 Glomerulonephritis Associated With Monoclonal Gammopathy: A Case Series. American Journal of Kidney Diseases, 2013, 62, 506-514.	1.9	150
2	COVID-19 Vaccination and Glomerulonephritis. Kidney International Reports, 2021, 6, 2969-2978.	0.8	135
3	Noninvasive diagnosis of primary membranous nephropathy using phospholipase A2 receptor antibodies. Kidney International, 2019, 95, 429-438.	5.2	123
4	Outcomes of patients with renal monoclonal immunoglobulin deposition disease. American Journal of Hematology, 2016, 91, 1123-1128.	4.1	76
5	Complement activation in pauci-immune necrotizing and crescentic glomerulonephritis: results of a proteomic analysis. Nephrology Dialysis Transplantation, 2017, 32, i139-i145.	0.7	59
6	Clinical and pathological phenotype of genetic causes of focal segmental glomerulosclerosis in adults. CKJ: Clinical Kidney Journal, 2018, 11, 179-190.	2.9	55
7	Successful Treatment of Patients With Refractory PLA2R-Associated Membranous Nephropathy With Obinutuzumab: A Report of 3 Cases. American Journal of Kidney Diseases, 2020, 76, 883-888.	1.9	45
8	Elevated urinary podocyte-derived extracellular microvesicles in renovascular hypertensive patients. Nephrology Dialysis Transplantation, 2017, 32, gfw077.	0.7	44
9	The Incidence of Primary vs Secondary Focal Segmental Glomerulosclerosis: A Clinicopathologic Study. Mayo Clinic Proceedings, 2017, 92, 1772-1781.	3.0	39
10	Rituximab in Membranous Nephropathy. Kidney International Reports, 2021, 6, 881-893.	0.8	39
11	Rituximab in adult minimal change disease and focal segmental glomerulosclerosis - What is known and what is still unknown?. Autoimmunity Reviews, 2020, 19, 102671.	5.8	37
12	Rate and Predictors of Finding Monoclonal Gammopathy of Renal Significance (MGRS) Lesions on Kidney Biopsy in Patients with Monoclonal Gammopathy. Journal of the American Society of Nephrology: JASN, 2020, 31, 2400-2411.	6.1	33
13	Safety and Efficacy of Daratumumab in Patients with Proliferative GN with Monoclonal Immunoglobulin Deposits. Journal of the American Society of Nephrology: JASN, 2021, 32, 1163-1173.	6.1	33
14	The Use of Vitamin D Metabolites and Analogues in the Treatment of Chronic Kidney Disease. Endocrinology and Metabolism Clinics of North America, 2017, 46, 983-1007.	3.2	29
15	Noninvasive Diagnosis of PLA2R-Associated Membranous Nephropathy. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 1833-1839.	4.5	27
16	Renal Tubular Acidosis and Immune Checkpoint Inhibitor Therapy: An Immune-Related Adverse Event of PD-1 Inhibitor – A Report of 3 Cases. Kidney Medicine, 2020, 2, 657-662.	2.0	26
17	Radiologic and Clinical Bronchiectasis Associated with Autosomal Dominant Polycystic Kidney Disease. PLoS ONE, 2014, 9, e93674.	2.5	24
18	Efficacy and safety of adrenocorticotrophic hormone treatment in glomerular diseases: a systematic review and meta-analysis. CKJ: Clinical Kidney Journal, 2016, 9, 387-396.	2.9	23

#	ARTICLE	IF	CITATIONS
19	Lactate clearance and metabolic aspects of continuous high-volume hemofiltration. CKJ: Clinical Kidney Journal, 2015, 8, 374-377.	2.9	22
20	Identification of Genetic Causes of Focal Segmental Glomerulosclerosis Increases With Proper Patient Selection. Mayo Clinic Proceedings, 2021, 96, 2342-2353.	3.0	20
21	The association of microhematuria with mesangial hypercellularity, endocapillary hypercellularity, crescent score and renal outcomes in immunoglobulin A nephropathy. Nephrology Dialysis Transplantation, 2021, 36, 840-847.	0.7	18
22	An Open-Label Pilot Study of Adrenocorticotrophic Hormone in the Treatment of IgA Nephropathy at High Risk of Progression. Kidney International Reports, 2020, 5, 58-65.	0.8	17
23	What are we missing in the clinical trials of focal segmental glomerulosclerosis?. Nephrology Dialysis Transplantation, 2017, 32, i14-i21.	0.7	15
24	Severe Anion Gap Metabolic Acidosis From Acetaminophen Use Secondary to 5-Oxoproline (Pyroglutamic Acid) Accumulation. American Journal of the Medical Sciences, 2012, 344, 501-504.	1.1	14
25	Genomics Integration Into Nephrology Practice. Kidney Medicine, 2021, 3, 785-798.	2.0	13
26	Recurrence of DNAJB9-Positive Fibrillary Glomerulonephritis After Kidney Transplantation: A Case Series. American Journal of Kidney Diseases, 2020, 76, 500-510.	1.9	13
27	Treatment of fibrillary glomerulonephritis with rituximab: a 12-month pilot study. Nephrology Dialysis Transplantation, 2021, 36, 104-110.	0.7	12
28	Standardized reporting of monoclonal immunoglobulin-associated renal diseases: recommendations from a Mayo Clinic/Renal Pathology Society Working Group. Kidney International, 2020, 98, 310-313.	5.2	7
29	Treatment of ANCA-Associated Vasculitis: New Therapies and a Look at Old Entities. Advances in Chronic Kidney Disease, 2014, 21, 182-193.	1.4	6
30	Serum Parathyroid Hormone Concentrations and Clinical Outcomes in ESRD: A Call for Targeted Clinical Trials. Seminars in Dialysis, 2016, 29, 184-188.	1.3	6
31	Validation of prognostic indices for short term mortality in an incident dialysis population of older adults >75. PLoS ONE, 2021, 16, e0244081.	2.5	6
32	Comparison of treatment options in adults with frequently relapsing or steroid-dependent minimal change disease. Nephrology Dialysis Transplantation, 2021, 36, 1821-1827.	0.7	5
33	Rituximab Is Preferable to Cyclophosphamide for Treatment of Membranous Nephropathy: COMMENTARY. Kidney360, 2021, 2, 1702-1705.	2.1	5
34	The Case Renal dysfunction in a pregnant patient with IgA nephropathy. Kidney International, 2014, 85, 1477-1478.	5.2	3
35	A Pregnant Woman With New-Onset Hypertension and Acute Kidney Injury. Kidney International Reports, 2022, 7, 924-929.	0.8	2
36	CYP24A1 deficiency causing persistent hypercalciuria in a stone former. Journal of Nephrology, 2021, 34, 949-951.	2.0	1

#	ARTICLE	IF	CITATIONS
37	Chronic lymphocytic leukemia and light chain proximal tubulopathy: A rare presentation of a common disease. <i>Journal of Onco-Nephrology</i> , 0, , 239936932210796.	0.6	1
38	Acquired thoracic kidney. <i>Kidney International</i> , 2020, 97, 811.	5.2	0
39	A Single-Center Phase 2 Open-Label Trial Evaluating the Safety and Efficacy of Daratumumab in Treatment of Patients with Monoclonal Gammopathy of Renal Significance. <i>Blood</i> , 2020, 136, 43-44.	1.4	0
40	Catastrophic kidney infarction. <i>Kidney International</i> , 2022, 101, 189.	5.2	0